Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 425066
Title Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
Author(s) Perez, O.; Batista-Duharte, A.; Gonzalez, E.; Zayas, C.; Balbao, J.; Cuello, M.; Cabrera, O.; Lastre, M.; Schijns, V.E.J.C.
Source Brazilian Journal of Medical and Biological Research 45 (2012)8. - ISSN 0100-879X - p. 681 - 692.
DOI https://doi.org/10.1590/S0100-879X2012007500067
Department(s) Cell Biology and Immunology
WIAS
Publication type Refereed Article in a scientific journal
Publication year 2012
Keyword(s) guillain-barre-syndrome - adaptive immunity - influenza vaccine - dendritic cells - subclass restriction - antibody-responses - innate immunity - t-cells - aluminum - inflammasome
Abstract Adjuvants have been considered for a long time to be an accessory and empirical component of vaccine formulations. However, accumulating evidence of their crucial role in initiating and directing the immune response has increased our awareness of the importance of adjuvant research in the past decade. Nevertheless, the importance of adjuvants still is not fully realized by many researchers working in the vaccine field, who are involved mostly in the search for better target antigens. The choice of a proper adjuvant can be determinant for obtaining the best results for a given vaccine candidate, but it is restricted due to intellectual property and know-how issues. Consequently, in most cases the selected adjuvant continues to be the aluminum salt, which has a record of safety, but predominantly constitutes a delivery system (DS). Ideally, new strategies should combine immune potentiators (IP) and DS by mixing both compounds or by obtaining structures that contain both IP and DS. In addition, the term immune polarizer has been introduced as an essential concept in the vaccine design strategies. Here, we review the theme, with emphasis on the discussion of the few licensed new adjuvants, the need for safe mucosal adjuvants and the adjuvant/immunopotentiating activity of conjugation. A summary of toxicology and regulatory issues will also be discussed, and the Finlay Adjuvant Platform is briefly summarized.
Comments
There are no comments yet. You can post the first one!
Post a comment
 
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.